
### [MONDO:0021254](http://purl.obolibrary.org/obo/MONDO_0021254)
**Label:** corpus uteri neoplasm

**Subclasses:** [MONDO:0003928](http://purl.obolibrary.org/obo/MONDO_0003928) (uterine corpus myxoid leiomyosarcoma), [MONDO:0002879](http://purl.obolibrary.org/obo/MONDO_0002879) (uterine body mixed cancer), [MONDO:0002878](http://purl.obolibrary.org/obo/MONDO_0002878) (uterine corpus adenosarcoma), [MONDO:0001745](http://purl.obolibrary.org/obo/MONDO_0001745) (subserous uterine fibroid), [MONDO:0001664](http://purl.obolibrary.org/obo/MONDO_0001664) (submucous uterine fibroid), [MONDO:0002876](http://purl.obolibrary.org/obo/MONDO_0002876) (cervical adenosarcoma), [MONDO:0001781](http://purl.obolibrary.org/obo/MONDO_0001781) (uterine corpus adenomatoid tumor), [MONDO:0007886](http://purl.obolibrary.org/obo/MONDO_0007886) (uterine corpus leiomyoma), [MONDO:0001783](http://purl.obolibrary.org/obo/MONDO_0001783) (endometrial stromal nodule), [MONDO:0004490](http://purl.obolibrary.org/obo/MONDO_0004490) (gestational uterine corpus choriocarcinoma), [MONDO:0004491](http://purl.obolibrary.org/obo/MONDO_0004491) (uterine corpus choriocarcinoma), [MONDO:0004172](http://purl.obolibrary.org/obo/MONDO_0004172) (uterine corpus adenocarcinofibroma), [MONDO:0016272](http://purl.obolibrary.org/obo/MONDO_0016272) (transitional cell carcinoma of the corpus uteri), [MONDO:0002923](http://purl.obolibrary.org/obo/MONDO_0002923) (uterine corpus endometrial stromal sarcoma), [MONDO:0016271](http://purl.obolibrary.org/obo/MONDO_0016271) (adenoid cystic carcinoma of the corpus uteri), [MONDO:0016273](http://purl.obolibrary.org/obo/MONDO_0016273) (malignant germ cell tumor of corpus uteri), [MONDO:0016270](http://purl.obolibrary.org/obo/MONDO_0016270) (low-grade neuroendocrine tumor of the corpus uteri), [MONDO:0003458](http://purl.obolibrary.org/obo/MONDO_0003458) (uterine corpus adenofibroma), [MONDO:0004221](http://purl.obolibrary.org/obo/MONDO_0004221) (uterine corpus perivascular epithelioid cell tumor), [MONDO:0004386](http://purl.obolibrary.org/obo/MONDO_0004386) (uterine corpus atypical polypoid adenomyoma), [MONDO:0006003](http://purl.obolibrary.org/obo/MONDO_0006003) (uterine corpus cancer), [MONDO:0016269](http://purl.obolibrary.org/obo/MONDO_0016269) (high-grade neuroendocrine carcinoma of the corpus uteri), [MONDO:0016268](http://purl.obolibrary.org/obo/MONDO_0016268) (papillary carcinoma of the corpus uteri), [MONDO:0016267](http://purl.obolibrary.org/obo/MONDO_0016267) (undifferentiated carcinoma of the corpus uteri), [MONDO:0016266](http://purl.obolibrary.org/obo/MONDO_0016266) (squamous cell carcinoma of the corpus uteri), [MONDO:0001845](http://purl.obolibrary.org/obo/MONDO_0001845) (uterine corpus lipoleiomyoma), [MONDO:0016260](http://purl.obolibrary.org/obo/MONDO_0016260) (uterine corpus rhabdomyosarcoma), [MONDO:0003629](http://purl.obolibrary.org/obo/MONDO_0003629) (uterine corpus serous adenocarcinoma), [MONDO:0001844](http://purl.obolibrary.org/obo/MONDO_0001844) (uterine corpus myxoid leiomyoma), [MONDO:0003703](http://purl.obolibrary.org/obo/MONDO_0003703) (uterine corpus leiomyomatosis), [MONDO:0016263](http://purl.obolibrary.org/obo/MONDO_0016263) (primitive neuroectodermal tumor of the corpus uteri), [MONDO:0003704](http://purl.obolibrary.org/obo/MONDO_0003704) (uterine corpus diffuse leiomyomatosis), [MONDO:0016262](http://purl.obolibrary.org/obo/MONDO_0016262) (leiomyosarcoma of the corpus uteri), [MONDO:0001846](http://purl.obolibrary.org/obo/MONDO_0001846) (uterine corpus bizarre leiomyoma), [MONDO:0000553](http://purl.obolibrary.org/obo/MONDO_0000553) (uterine corpus endometrial carcinoma), [MONDO:0001841](http://purl.obolibrary.org/obo/MONDO_0001841) (uterine corpus epithelioid leiomyoma), [MONDO:0003702](http://purl.obolibrary.org/obo/MONDO_0003702) (uterus intravascular leiomyomatosis), [MONDO:0001843](http://purl.obolibrary.org/obo/MONDO_0001843) (uterus interstitial leiomyoma), [MONDO:0001842](http://purl.obolibrary.org/obo/MONDO_0001842) (uterine corpus dissecting leiomyoma), [MONDO:0003782](http://purl.obolibrary.org/obo/MONDO_0003782) (uterine corpus epithelioid leiomyosarcoma), [MONDO:0021650](http://purl.obolibrary.org/obo/MONDO_0021650) (uterine corpus neuroendocrine neoplasm), [MONDO:0004792](http://purl.obolibrary.org/obo/MONDO_0004792) (isthmus cancer), [MONDO:0016258](http://purl.obolibrary.org/obo/MONDO_0016258) (uterine corpus carcinofibroma), [MONDO:0016257](http://purl.obolibrary.org/obo/MONDO_0016257) (adenosarcoma of the corpus uteri), [MONDO:0016259](http://purl.obolibrary.org/obo/MONDO_0016259) (carcinosarcoma of the corpus uteri), [MONDO:0016255](http://purl.obolibrary.org/obo/MONDO_0016255) (uterine corpus mixed epithelial and mesenchymal neoplasm), [MONDO:0004526](http://purl.obolibrary.org/obo/MONDO_0004526) (mixed endometrial stromal and smooth muscle tumor), [MONDO:0003237](http://purl.obolibrary.org/obo/MONDO_0003237) (adenomyoma of uterine corpus), [MONDO:0021525](http://purl.obolibrary.org/obo/MONDO_0021525) (benign neoplasm of corpus uteri), [MONDO:0005210](http://purl.obolibrary.org/obo/MONDO_0005210) (uterine corpus sarcoma), [MONDO:0004162](http://purl.obolibrary.org/obo/MONDO_0004162) (uterine corpus cellular leiomyoma), [MONDO:0004161](http://purl.obolibrary.org/obo/MONDO_0004161) (uterine corpus apoplectic leiomyoma), 

**Mapped go classes:** [GO:0008283](http://purl.obolibrary.org/obo/GO_0008283) (cell proliferation), [GO:0060441](http://purl.obolibrary.org/obo/GO_0060441) (epithelial tube branching involved in lung morphogenesis), [GO:0060123](http://purl.obolibrary.org/obo/GO_0060123) (regulation of growth hormone secretion), [GO:0006284](http://purl.obolibrary.org/obo/GO_0006284) (base-excision repair), [GO:0033144](http://purl.obolibrary.org/obo/GO_0033144) (negative regulation of intracellular steroid hormone receptor signaling pathway), [GO:0008584](http://purl.obolibrary.org/obo/GO_0008584) (male gonad development), [GO:0090276](http://purl.obolibrary.org/obo/GO_0090276) (regulation of peptide hormone secretion), [GO:0008284](http://purl.obolibrary.org/obo/GO_0008284) (positive regulation of cell proliferation), [GO:0048712](http://purl.obolibrary.org/obo/GO_0048712) (negative regulation of astrocyte differentiation), [GO:0060428](http://purl.obolibrary.org/obo/GO_0060428) (lung epithelium development), [GO:0051091](http://purl.obolibrary.org/obo/GO_0051091) (positive regulation of DNA binding transcription factor activity), [GO:0045944](http://purl.obolibrary.org/obo/GO_0045944) (positive regulation of transcription by RNA polymerase II), [GO:0040018](http://purl.obolibrary.org/obo/GO_0040018) (positive regulation of multicellular organism growth), [GO:0045766](http://purl.obolibrary.org/obo/GO_0045766) (positive regulation of angiogenesis), [GO:0060501](http://purl.obolibrary.org/obo/GO_0060501) (positive regulation of epithelial cell proliferation involved in lung morphogenesis), [GO:0051301](http://purl.obolibrary.org/obo/GO_0051301) (cell division), [GO:0000122](http://purl.obolibrary.org/obo/GO_0000122) (negative regulation of transcription by RNA polymerase II), [GO:0051321](http://purl.obolibrary.org/obo/GO_0051321) (meiotic cell cycle), [GO:0001077](http://purl.obolibrary.org/obo/GO_0001077) (transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding), [GO:0003700](http://purl.obolibrary.org/obo/GO_0003700) (DNA binding transcription factor activity), [GO:0035019](http://purl.obolibrary.org/obo/GO_0035019) (somatic stem cell population maintenance), [GO:0003906](http://purl.obolibrary.org/obo/GO_0003906) (DNA-(apurinic or apyrimidinic site) lyase activity), [GO:0030325](http://purl.obolibrary.org/obo/GO_0030325) (adrenal gland development), [GO:2000773](http://purl.obolibrary.org/obo/GO_2000773) (negative regulation of cellular senescence), [GO:0021846](http://purl.obolibrary.org/obo/GO_0021846) (cell proliferation in forebrain), [GO:0007165](http://purl.obolibrary.org/obo/GO_0007165) (signal transduction), [GO:0006351](http://purl.obolibrary.org/obo/GO_0006351) (transcription, DNA-templated), [GO:0007283](http://purl.obolibrary.org/obo/GO_0007283) (spermatogenesis), [GO:0030261](http://purl.obolibrary.org/obo/GO_0030261) (chromosome condensation), [GO:0060613](http://purl.obolibrary.org/obo/GO_0060613) (fat pad development), [GO:0003680](http://purl.obolibrary.org/obo/GO_0003680) (AT DNA binding), [GO:0006355](http://purl.obolibrary.org/obo/GO_0006355) (regulation of transcription, DNA-templated), [GO:0000228](http://purl.obolibrary.org/obo/GO_0000228) (nuclear chromosome), [GO:0000785](http://purl.obolibrary.org/obo/GO_0000785) (chromatin), [GO:0040008](http://purl.obolibrary.org/obo/GO_0040008) (regulation of growth), [GO:0046426](http://purl.obolibrary.org/obo/GO_0046426) (negative regulation of JAK-STAT cascade), [GO:0007049](http://purl.obolibrary.org/obo/GO_0007049) (cell cycle), [GO:0021983](http://purl.obolibrary.org/obo/GO_0021983) (pituitary gland development), [GO:0060612](http://purl.obolibrary.org/obo/GO_0060612) (adipose tissue development), [GO:0003677](http://purl.obolibrary.org/obo/GO_0003677) (DNA binding), [GO:0005634](http://purl.obolibrary.org/obo/GO_0005634) (nucleus), [GO:0005515](http://purl.obolibrary.org/obo/GO_0005515) (protein binding), [GO:2000648](http://purl.obolibrary.org/obo/GO_2000648) (positive regulation of stem cell proliferation), [GO:0010628](http://purl.obolibrary.org/obo/GO_0010628) (positive regulation of gene expression), [GO:0071864](http://purl.obolibrary.org/obo/GO_0071864) (positive regulation of cell proliferation in bone marrow), [GO:0030178](http://purl.obolibrary.org/obo/GO_0030178) (negative regulation of Wnt signaling pathway), [GO:0019899](http://purl.obolibrary.org/obo/GO_0019899) (enzyme binding), [GO:0010564](http://purl.obolibrary.org/obo/GO_0010564) (regulation of cell cycle process), 

**Class expressions from DL-Learner:**

- [GO:2000773](http://purl.obolibrary.org/obo/GO_2000773) (negative regulation of cellular senescence) 54.55%
- [GO:0090344](http://purl.obolibrary.org/obo/GO_0090344) (negative regulation of cell aging) 54.55%
- [GO:0060613](http://purl.obolibrary.org/obo/GO_0060613) (fat pad development) 54.55%
- [GO:0060612](http://purl.obolibrary.org/obo/GO_0060612) (adipose tissue development) 54.55%
- [GO:0048232](http://purl.obolibrary.org/obo/GO_0048232) (male gamete generation) 54.55%
- [GO:0040018](http://purl.obolibrary.org/obo/GO_0040018) (positive regulation of multicellular organism growth) 54.55%
- [GO:0030325](http://purl.obolibrary.org/obo/GO_0030325) (adrenal gland development) 54.55%
- [GO:0021983](http://purl.obolibrary.org/obo/GO_0021983) (pituitary gland development) 54.55%
- [GO:0008584](http://purl.obolibrary.org/obo/GO_0008584) (male gonad development) 54.55%
- [GO:0007283](http://purl.obolibrary.org/obo/GO_0007283) (spermatogenesis) 54.55%
- [GO:0090344](http://purl.obolibrary.org/obo/GO_0090344) (negative regulation of cell aging) and [GO:2000772](http://purl.obolibrary.org/obo/GO_2000772) (regulation of cellular senescence) 54.55%
- [GO:0080135](http://purl.obolibrary.org/obo/GO_0080135) (regulation of cellular response to stress) and [GO:0090344](http://purl.obolibrary.org/obo/GO_0090344) (negative regulation of cell aging) 54.55%
- [GO:0080134](http://purl.obolibrary.org/obo/GO_0080134) (regulation of response to stress) and [GO:0090344](http://purl.obolibrary.org/obo/GO_0090344) (negative regulation of cell aging) 54.55%
- [GO:0051093](http://purl.obolibrary.org/obo/GO_0051093) (negative regulation of developmental process) and [GO:2000772](http://purl.obolibrary.org/obo/GO_2000772) (regulation of cellular senescence) 54.55%
- [GO:0051093](http://purl.obolibrary.org/obo/GO_0051093) (negative regulation of developmental process) and [GO:0090342](http://purl.obolibrary.org/obo/GO_0090342) (regulation of cell aging) 54.55%


